These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 3259680)

  • 21. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
    Miladinović D; Paunović R; Paunković N
    Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of CA 125 in comparison to conventional tumor markers in ovarian cancer].
    Paulick R; Kaesemann H; Caffier H
    Geburtshilfe Frauenheilkd; 1986 Aug; 46(8):509-14. PubMed ID: 2875919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
    Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
    Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of CA 125 determination in the serum of patients with ovarian cancer].
    Bartel U; Johannsen B; Elling D
    Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
    Hefler LA; Concin N; Hofstetter G; Marth C; Mustea A; Sehouli J; Zeillinger R; Leipold H; Lass H; Grimm C; Tempfer CB; Reinthaller A
    Clin Cancer Res; 2008 Feb; 14(3):710-4. PubMed ID: 18245530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data.
    Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
    J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunosuppressive acidic protein (IAP) in gynecologic malignant tumors and its relationship with other immunosuppressive substances and cell-mediated immunity].
    Takada M
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):237-44. PubMed ID: 6881975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunosuppressive acidic protein in patients with gynecologic cancer].
    Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 May; 35(5):605-11. PubMed ID: 6408203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
    Suzuki M; Sekiguchi I; Tamada T
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
    Sawada M; Okudaira Y; Matsui Y; Miyoshi Y; Takayama K; Shimizu Y; Miura S
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
    Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
    Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies on immunosuppressive acidic protein (IAP) in ovarian tumors].
    Miyoshi T; Nishimura H; Hamai J; Yamada T; Tomoo Y; Kobayashi H; Yakushiji M; Kato T
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):923-9. PubMed ID: 2991397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of immunosuppressive acid protein in genitourinary malignant diseases].
    Okada S; Kirime S; Kawasaki T; Kanbara A; Kanehara H; Takasaki N; Miyazaki S; Inai S
    Hinyokika Kiyo; 1988 Mar; 34(3):411-8. PubMed ID: 3389287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serologic monitoring of patients with endometrial carcinoma using ovarian carcinoma antigen (CA 125)].
    Göcze P; Varhson H
    Orv Hetil; 1993 Mar; 134(13):685-8. PubMed ID: 8460017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.